Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease
© 2022 John Wiley & Sons Ltd..
BACKGROUND: It is unclear whether improvement in patient-reported outcomes (PROs) relative to baseline symptom burden in Crohn's disease (CD) is associated with subsequent endoscopic remission.
AIM: To evaluate the relationship between dominant PRO resolution post-induction and achievement of clinical and endoscopic remission.
METHODS: This post-hoc analysis of clinical trial data from 251 participants evaluated the relationship between the resolution of the dominant PRO (most severely elevated baseline PRO) or clinical response (CDAI ≥100 reduction) after induction therapy with biologics (post-induction) and 1-year clinical remission (CDAI <150) and/or endoscopic remission (SES-CD <3). Multivariate logistic regression models evaluated the relationship between post-induction-dominant PRO resolution and 1-year outcomes adjusted for confounders.
RESULTS: Participants with dominant PRO resolution post-induction had higher odds of combined endoscopic and clinical remission compared to those without resolution (aOR: 1.94 [95% CI: 1.01-3.74], P = 0.047). Combining dominant PRO resolution with post-induction endoscopic response (SES-CD ≥50% reduction) was associated with higher odds of 1-year endoscopic and clinical remission (aOR: 6.89 [95% CI: 1.65-28.72], P = 0.008). Clinical and PRO2 response (≥30% decrease in stool frequency and/or ≥30% decrease in abdominal pain score and both not worse than baseline) at post-induction did not predict these outcomes. No significant differences were observed with 1-year endoscopic remission for post-induction-dominant PRO resolution, clinical or PRO2 response.
CONCLUSIONS: Post-induction resolution of dominant PRO, but not clinical or PRO2 response, was strongly associated with 1-year endoscopic and clinical remission. Resolution of dominant baseline PRO after induction therapy may be informative for 1-year outcomes. Further validation is required.
| Errataetall: |
CommentIn: Aliment Pharmacol Ther. 2022 Apr;55(8):1038-1039. - PMID 35362139 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 55(2022), 9 vom: 19. Mai, Seite 1151-1159 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wong, Emily C L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological Products |
|---|
| Anmerkungen: |
Date Completed 19.04.2022 Date Revised 11.11.2023 published: Print-Electronic CommentIn: Aliment Pharmacol Ther. 2022 Apr;55(8):1038-1039. - PMID 35362139 Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.16805 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33698460X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33698460X | ||
| 003 | DE-627 | ||
| 005 | 20231225233403.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.16805 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM33698460X | ||
| 035 | |a (NLM)35166396 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wong, Emily C L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2022 | ||
| 500 | |a Date Revised 11.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Aliment Pharmacol Ther. 2022 Apr;55(8):1038-1039. - PMID 35362139 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: It is unclear whether improvement in patient-reported outcomes (PROs) relative to baseline symptom burden in Crohn's disease (CD) is associated with subsequent endoscopic remission | ||
| 520 | |a AIM: To evaluate the relationship between dominant PRO resolution post-induction and achievement of clinical and endoscopic remission | ||
| 520 | |a METHODS: This post-hoc analysis of clinical trial data from 251 participants evaluated the relationship between the resolution of the dominant PRO (most severely elevated baseline PRO) or clinical response (CDAI ≥100 reduction) after induction therapy with biologics (post-induction) and 1-year clinical remission (CDAI <150) and/or endoscopic remission (SES-CD <3). Multivariate logistic regression models evaluated the relationship between post-induction-dominant PRO resolution and 1-year outcomes adjusted for confounders | ||
| 520 | |a RESULTS: Participants with dominant PRO resolution post-induction had higher odds of combined endoscopic and clinical remission compared to those without resolution (aOR: 1.94 [95% CI: 1.01-3.74], P = 0.047). Combining dominant PRO resolution with post-induction endoscopic response (SES-CD ≥50% reduction) was associated with higher odds of 1-year endoscopic and clinical remission (aOR: 6.89 [95% CI: 1.65-28.72], P = 0.008). Clinical and PRO2 response (≥30% decrease in stool frequency and/or ≥30% decrease in abdominal pain score and both not worse than baseline) at post-induction did not predict these outcomes. No significant differences were observed with 1-year endoscopic remission for post-induction-dominant PRO resolution, clinical or PRO2 response | ||
| 520 | |a CONCLUSIONS: Post-induction resolution of dominant PRO, but not clinical or PRO2 response, was strongly associated with 1-year endoscopic and clinical remission. Resolution of dominant baseline PRO after induction therapy may be informative for 1-year outcomes. Further validation is required | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Crohn’s disease | |
| 650 | 4 | |a inflammatory bowel disease | |
| 650 | 4 | |a patient-reported outcomes | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 700 | 1 | |a Dulai, Parambir S |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, John K |e verfasserin |4 aut | |
| 700 | 1 | |a Jairath, Vipul |e verfasserin |4 aut | |
| 700 | 1 | |a Reinisch, Walter |e verfasserin |4 aut | |
| 700 | 1 | |a Narula, Neeraj |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 55(2022), 9 vom: 19. Mai, Seite 1151-1159 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2022 |g number:9 |g day:19 |g month:05 |g pages:1151-1159 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.16805 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2022 |e 9 |b 19 |c 05 |h 1151-1159 | ||